Stockwatch: The impossible takes a little too long

When Tony Blair joined Bill Clinton by satellite link to the White House in 2000 to announce the sequencing of the human genome, biotech stocks soared with the implication that genomics would result in a cure for any disease. Even today, nearly twelve years, recently approved targeted therapies for blood and skin cancers imply that the application of genomic data and molecular biology can result in a treatment for most unmet clinical needs, eventually.

Eventually is however, a long time and while many will recognise it from the school of forward-looking statements, it is...